Comparison of killing effects of cytokine-induced killer cell from three different sources on hepatoma cell SMMC7721

Objective To explore the reproductive activity in vitro and killing effects to hepatoma cell SMMC7721 of cytokine-induced killer cell(CIK) from cord blood,peripheral blood of health people and liver cancer patients.Methods The cord blood and peripheral blood of health people and patients with hepatoma were collected under asepsis condition and the mononuclear cells were separated by lydroxypropylmethyl cellulose.CIK were induced by adding a variety of cytokine in different time.The reproductive activity of CIK were measured by cell counting.Flow cytometry was used to detect the cell phenotype of CIK.The methyl thiazolyl tetrazolium was used to detect the killing effect of CIK to SMMC7721 cells.Results After 14 days of induction,the proliferation multiple of CIK from cord blood,peripheral blood of health people and liver cancer patients was 153.813.1,137.6±10.3 and 95.3±8.5 respectively,the difference of them was statistic significance(P0.05).After 14 days of induction and cultivation,the percentage of mononuclear cells with CD3~+ CD56~+ phenotype from cord blood,peripheral blood of health people and liver cancer patients was(45.3 ±4.6)%,(36.2±2.8)%,(21.9±2.7)%respectively, and it was significantly higher than before induction(P0.05);the percentage of mononuclear cells with CD3~+ CD56~+ phenotype from cord blood was significantly higher than that from peripheral blood of health people and liver cancer patients(P0.05).After 14 days induction and cultivation,the differences of the killing effect of CIK from three source to hepatoma cell SMMC7721 cells were statistic significance(P0.05).The killing activity of cord blood was strongest,health people followed, liver cancer patients was weakest.The killing activity at effect-target ratios 10:1 was stronger than at 5:1(P 0.05).Conclusion CIK derived from cord blood possess high speed of proliferation in vitro and strong killing effect to hepatoma cell SMMC7721,thus being the best choice for tumor biologic therapy.